Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1952 1
1963 1
1964 2
1965 1
1966 1
1967 1
1968 1
1969 2
1970 1
1971 2
1972 3
1973 3
1974 1
1975 6
1976 2
1977 2
1978 1
1979 2
1980 4
1981 1
1982 1
1983 6
1984 8
1985 10
1986 12
1987 10
1988 5
1989 17
1990 13
1991 16
1992 19
1993 16
1994 20
1995 14
1996 22
1997 21
1998 32
1999 38
2000 34
2001 36
2002 32
2003 25
2004 22
2005 21
2006 24
2007 36
2008 45
2009 46
2010 58
2011 81
2012 86
2013 92
2014 73
2015 87
2016 68
2017 58
2018 65
2019 82
2020 100
2021 104
2022 82
2023 70
2024 83
2025 38

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,655 results

Results by year

Filters applied: . Clear all
Page 1
Tumor-Derived Retinoic Acid Regulates Intratumoral Monocyte Differentiation to Promote Immune Suppression.
Devalaraja S, To TKJ, Folkert IW, Natesan R, Alam MZ, Li M, Tada Y, Budagyan K, Dang MT, Zhai L, Lobel GP, Ciotti GE, Eisinger-Mathason TSK, Asangani IA, Weber K, Simon MC, Haldar M. Devalaraja S, et al. Among authors: tada y. Cell. 2020 Mar 19;180(6):1098-1114.e16. doi: 10.1016/j.cell.2020.02.042. Epub 2020 Mar 12. Cell. 2020. PMID: 32169218 Free PMC article.
Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus.
Yin X, Kim K, Suetsugu H, Bang SY, Wen L, Koido M, Ha E, Liu L, Sakamoto Y, Jo S, Leng RX, Otomo N, Laurynenka V, Kwon YC, Sheng Y, Sugano N, Hwang MY, Li W, Mukai M, Yoon K, Cai M, Ishigaki K, Chung WT, Huang H, Takahashi D, Lee SS, Wang M, Karino K, Shim SC, Zheng X, Miyamura T, Kang YM, Ye D, Nakamura J, Suh CH, Tang Y, Motomura G, Park YB, Ding H, Kuroda T, Choe JY, Li C, Niiro H, Park Y, Shen C, Miyamoto T, Ahn GY, Fei W, Takeuchi T, Shin JM, Li K, Kawaguchi Y, Lee YK, Wang Y, Amano K, Park DJ, Yang W, Tada Y, Yamaji K, Shimizu M, Atsumi T, Suzuki A, Sumida T, Okada Y, Matsuda K, Matsuo K, Kochi Y; Japanese Research Committee on Idiopathic Osteonecrosis of the Femoral Head; Kottyan LC, Weirauch MT, Parameswaran S, Eswar S, Salim H, Chen X, Yamamoto K, Harley JB, Ohmura K, Kim TH, Yang S, Yamamoto T, Kim BJ, Shen N, Ikegawa S, Lee HS, Zhang X, Terao C, Cui Y, Bae SC. Yin X, et al. Among authors: tada y. Ann Rheum Dis. 2021 May;80(5):632-640. doi: 10.1136/annrheumdis-2020-219209. Epub 2020 Dec 3. Ann Rheum Dis. 2021. PMID: 33272962 Free PMC article.
Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan.
Jo T, Yoshihara S, Okuyama Y, Fujii K, Henzan T, Kahata K, Yamazaki R, Takeda W, Umezawa Y, Fukushima K, Ashida T, Yamada-Fujiwara M, Hanajiri R, Yonetani N, Tada Y, Shimura Y, Nishikii H, Shiba N, Mimura N, Ando J, Sato T, Nakashima Y, Ikemoto J, Iwaki K, Fujiwara SI, Ri M, Nagamura-Inoue T, Tanosaki R, Arai Y. Jo T, et al. Among authors: tada y. Br J Haematol. 2023 Jul;202(2):256-266. doi: 10.1111/bjh.18831. Epub 2023 Apr 25. Br J Haematol. 2023. PMID: 37096915 Free article.
PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.
Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, Sato E, Fukuoka S, Tada Y, Tanaka A, Morikawa H, Kawazoe A, Kinoshita T, Shitara K, Sakaguchi S, Nishikawa H. Kamada T, et al. Among authors: tada y. Proc Natl Acad Sci U S A. 2019 May 14;116(20):9999-10008. doi: 10.1073/pnas.1822001116. Epub 2019 Apr 26. Proc Natl Acad Sci U S A. 2019. PMID: 31028147 Free PMC article.
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
Blauvelt A, Leonardi C, Elewski B, Crowley JJ, Guenther LC, Gooderham M, Langley RG, Vender R, Pinter A, Griffiths CEM, Tada Y, Elmaraghy H, Lima RG, Gallo G, Renda L, Burge R, Park SY, Zhu B, Papp K; IXORA-R Study Group. Blauvelt A, et al. Among authors: tada y. Br J Dermatol. 2021 Jun;184(6):1047-1058. doi: 10.1111/bjd.19509. Epub 2020 Oct 25. Br J Dermatol. 2021. PMID: 32880909 Free PMC article. Clinical Trial.
Immunoresponses in dermatomycoses.
Hau CS, Tada Y, Kanda N, Watanabe S. Hau CS, et al. Among authors: tada y. J Dermatol. 2015 Mar;42(3):236-44. doi: 10.1111/1346-8138.12718. J Dermatol. 2015. PMID: 25736316 Review.
1,655 results